Investing.com··Tim BakerModerna Surges on Hantavirus Vaccine Success, Signaling mRNA Platform Diversification
Moderna stock rises after positive Phase 1 hantavirus vaccine data, with analysts raising price targets amid signs of mRNA platform diversification beyond COVID.
MRNAclinical trialpipeline expansion